Literature DB >> 24958939

Paclitaxel and trastuzumab for breast cancer.

Thomas Lehmann1, Dominic A Solimando1, J Aubrey Waddell1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2014        PMID： 24958939      PMCID： PMC4062745          DOI： 10.1310/hpj4904-338

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  25 in total

1.  Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

Authors:  A D Seidman; M N Fornier; F J Esteva; L Tan; S Kaptain; A Bach; K S Panageas; C Arroyo; V Valero; V Currie; T Gilewski; M Theodoulou; M E Moynahan; M Moasser; N Sklarin; M Dickler; G D'Andrea; M Cristofanilli; E Rivera; G N Hortobagyi; L Norton; C A Hudis
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 3.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

Review 4.  Hepatotoxicity of chemotherapy.

Authors:  P D King; M C Perry
Journal:  Oncologist       Date:  2001

5.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

Authors:  Nicholas Robert; Brian Leyland-Jones; Lina Asmar; Robert Belt; Des Ilegbodu; David Loesch; Robert Raju; Elizabeth Valentine; Robert Sayre; Melody Cobleigh; Kathy Albain; Cecelia McCullough; Lea Fuchs; Dennis Slamon
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

6.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.

Authors:  Brian Leyland-Jones; Karen Gelmon; Jean-Pierre Ayoub; Andrew Arnold; Shail Verma; Reg Dias; Parviz Ghahramani
Journal:  J Clin Oncol       Date:  2003-09-24       Impact factor: 44.544

Review 8.  Hepatotoxicity of chemotherapy.

Authors:  Justin Floyd; Irfan Mirza; Bradley Sachs; Michael C Perry
Journal:  Semin Oncol       Date:  2006-02       Impact factor: 4.929

9.  Hypersensitivity reactions from taxol.

Authors:  R B Weiss; R C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; J R Baker; D A Van Echo; D D Von Hoff; B Leyland-Jones
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

10.  Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines--a phase II multipractice study.

Authors:  Matthias John; Axel Hinke; Martina Stauch; Heiner Wolf; Benno Mohr; Hans-Joachim Hindenburg; Jens Papke; Joachim Schlosser
Journal:  BMC Cancer       Date:  2012-05-04       Impact factor: 4.430
View more
  1 in total

1.  Actein Inhibits Tumor Growth and Metastasis in HER2-Positive Breast Tumor Bearing Mice via Suppressing AKT/mTOR and Ras/Raf/MAPK Signaling Pathways.

Authors:  Xiao-Xiao Wu; Grace Gar-Lee Yue; Jin-Run Dong; Christopher Wai-Kei Lam; Chun-Kwok Wong; Ming-Hua Qiu; Clara Bik-San Lau
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.